Klinik fanlar yilnomasi 3-том 1-нөмір (2026)

MAIN OBSTETRIC COMPLICATIONS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME (LITERATURE REVIEW)

Зарипов Ш.Ш, Султонова Н.А, Зарипова Д.Я

Дереккөзден оқу PDF

Аңдатпа

APS (antiphospholipid syndrome) is a disruption of the body's autoimmune response, manifesting as miscarriages and thromboembolic complications during pregnancy.  It is associated with a high risk of obstetric and perinatal complications. It primarily affects blood circulation in the fetoplacental system. Thrombuses formed as a result of autoimmune reactions damage the walls of the endothelium in the entire body, in particular, in the blood vessels, as in the placenta and in the vessels of the trophoblast, which can lead to antenatal fetal death or miscarriage at an early stage of gestation.

APS (antiphospholipid syndrome), miscarriage, pregnancy, thromboembolic complicationsАФС (антифосфолипидный синдром), выкидыш, беременность, тромбоэмболические осложненияAFS (antifosfolipid sindromi), bola tushishi, homiladorlik, tromboembolik asoratlar

Метадеректер дереккөзі: журналдың OAI-PMH архиві · Sindex толық мәтінді сақтамайды, дереккөзге сілтеме береді.

Дәйексөз алу

APA 7 
Зарипов Ш.Ш, Султонова Н.А & Зарипова Д.Я (2026). MAIN OBSTETRIC COMPLICATIONS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME (LITERATURE REVIEW). Klinik fanlar yilnomasi, 3(1).
GOST R 7.0.5 
Зарипов Ш.Ш, Султонова Н.А, Зарипова Д.Я MAIN OBSTETRIC COMPLICATIONS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME (LITERATURE REVIEW) // Klinik fanlar yilnomasi. 2026. Т. 3. № 1.
BibTeX 
@article{ш.ш2026,
  author  = {Зарипов Ш.Ш and Султонова Н.А and Зарипова Д.Я},
  title   = {MAIN OBSTETRIC COMPLICATIONS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME (LITERATURE REVIEW)},
  journal = {Klinik fanlar yilnomasi},
  year    = {2026},
  volume  = {3},
  number  = {1}
}
RIS 
TY  - JOUR
AU  - Зарипов Ш.Ш
AU  - Султонова Н.А
AU  - Зарипова Д.Я
TI  - MAIN OBSTETRIC COMPLICATIONS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME (LITERATURE REVIEW)
JO  - Klinik fanlar yilnomasi
PY  - 2026
VL  - 3
IS  - 1
ER  -